Related Experiment Video

Updated: Aug 28, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K

The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?

Kelly A Mills1, Gregory M Pontone2

  • 1Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|September 14, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
06:32

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Published on: July 14, 2023

1.4K
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

9.0K

Related Experiment Videos

Last Updated: Aug 28, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K
Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
06:32

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Published on: July 14, 2023

1.4K
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

9.0K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

355
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
355
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

677
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
677

Articles linked to this work by shared authors, journal, and citation graph.

Assessing Microstructural and Molecular Brain Changes in Early Cognitive Decline Using Multiparametric 3T Magnetic Resonance Imaging.

Neurology international·2026

A framework for multidisciplinary management of autonomic dysfunction in Parkinson disease.

Parkinsonism & related disorders·2026

Determinants of Deep Brain Stimulation Candidacy Failure in Movement Disorders: A Multidisciplinary Analysis.

Movement disorders clinical practice·2026

Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis.

Movement disorders clinical practice·2026

Apathy in dementia with Lewy bodies: Frequency, correlates, and impact on patient and caregiver experiences.

Parkinsonism & related disorders·2026

Living with the Unknown: Intolerance of Uncertainty in Parkinson's Disease.

Movement disorders clinical practice·2026

Multilevel Structure-Function Coupling Reveals Network Signatures of Remission in Paroxysmal Kinesigenic Dyskinesia.

Movement disorders : official journal of the Movement Disorder Society·2026

Association Between Long-Term Exposure to Air Pollution and Parkinson's Disease: Administrative Cohort of Older Adults in South Korea.

Movement disorders : official journal of the Movement Disorder Society·2026

Cross-Ethnic Replication of Intersectin-1 as a Parkinson's Disease Susceptibility Gene in a Large Chinese Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026

ATXN8OS Intermediate Expansion Acts as a Genetic Modifier in Spinocerebellar Ataxia Type 48 (SCA48/STUB1).

Movement disorders : official journal of the Movement Disorder Society·2026

Striatal Dopaminergic Reserve Shapes the Longitudinal Impact of Peripheral Immune Activation on Motor Progression in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Urine-Derived Neuronal Extracellular Vesicle α-Synuclein Seed Amplification Assay for Synucleinopathies: A Non-Invasive Biomarker Study.

Movement disorders : official journal of the Movement Disorder Society·2026

Network meta-analysis of intrathyroidal injection of combined dexamethasone with lidocaine for subacute thyroiditis.

Medicine·2026

Ritonavir-Loaded PEG-b-PCL Polymeric Micelles: Reduced Excipient Requirements and Comparable Oral Pharmacokinetics in Rats.

Pharmaceuticals (Basel, Switzerland)·2026

Protein Therapeutic Quality Control Using Multi-Attribute Method (MAM): Challenges and Current Practice in cGMP Environments.

Pharmaceuticals (Basel, Switzerland)·2026

Development and Evaluation of a Novel Inhalable Liposomal Powder Co-Encapsulating ASSNAC and Pirfenidone via Spray Freeze-Drying for Targeted Pulmonary Fibrosis Therapy.

Pharmaceuticals (Basel, Switzerland)·2026

PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives.

Pharmaceuticals (Basel, Switzerland)·2026

Formulation Screening and Characterization of PLGA-Based Injectable In Situ Gel Loaded with Progesterone.

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us